Animal Health Leader Zoetis to Acquire Animal Genomics Unit from Neogen, Advancing Precision Innovation
Zoetis, the world’s leading animal health company, has announced that it has entered into a definitive agreement with Neogen Corporation (NASDAQ: NEOG) to acquire Neogen’s animal genomics business for $160 million, subject to customary closing adjustments. The transaction marks a significant strategic step for Zoetis as it continues to strengthen its position at the forefront of livestock innovation through advanced genomics and data-driven animal health solutions.
The acquisition directly supports Zoetis’ long-term strategy to accelerate growth in Precision Animal Health, a rapidly evolving segment focused on delivering predictive insights, individualized animal care, and improved productivity outcomes. By integrating Neogen’s genomics assets into its portfolio, Zoetis aims to enhance its ability to provide livestock producers and companion animal customers with cutting-edge genetic tools that drive smarter breeding, better health management, and more sustainable production systems.
Neogen’s animal genomics business has built a strong global presence, serving customers in more than 120 countries. Its operations are supported by five strategically located laboratories in the United States, Brazil, Australia, China, and the United Kingdom, along with an office in Canada. This global footprint has enabled the business to deliver scalable and highly reliable genetic testing services across key livestock markets and species. Through this acquisition, Zoetis will gain access to a well-established infrastructure and customer base that spans major agricultural regions worldwide.
At the core of Neogen’s genomics business is a comprehensive genotyping platform that combines fixed array technologies and advanced sequencing capabilities. These technologies allow for highly accurate and efficient genetic analysis, enabling producers and breeders to make informed, data-driven decisions. In addition to laboratory capabilities, the business offers software solutions that transform complex genomic data into actionable insights. These digital tools help customers identify desirable traits, improve herd performance, reduce disease risk, and optimize breeding strategies.
The business is widely recognized as a leader in U.S. beef and dairy genomics, two of the most economically significant segments within the livestock industry. Its genetic testing solutions support producers in selecting animals with superior performance characteristics, including enhanced growth rates, feed efficiency, reproductive performance, and disease resistance. By leveraging cutting-edge technologies, Neogen’s genomics platform enables deeper insights into animal health, productivity, and sustainability, aligning closely with the evolving needs of modern agriculture.
For Zoetis, the addition of these capabilities significantly expands its existing Precision Animal Health portfolio. Precision Animal Health integrates genetics, diagnostics, data analytics, and digital tools to deliver tailored solutions for individual animals and herds. By combining Neogen’s genomic technologies with Zoetis’ extensive expertise in vaccines, medicines, diagnostics, and on-farm services, the company is positioned to offer a more comprehensive and integrated approach to animal health management.
Jamie Brannan, Chief Commercial Officer at Zoetis, emphasized the strategic importance of the transaction. He noted that the acquisition strengthens the company’s commitment to advancing animal health through innovation, data, and technology. As Zoetis continues to invest in next-generation solutions, the addition of Neogen’s genomics business brings complementary capabilities that enhance predictive insights and individualized care. This integration is expected to create new opportunities to deliver measurable value to customers while reinforcing Zoetis’ leadership in the industry.
The livestock sector is undergoing significant transformation, driven by increasing global demand for animal protein, heightened sustainability expectations, and growing pressure to improve efficiency. Genomics plays a critical role in addressing these challenges by enabling producers to identify and propagate desirable traits with greater precision and speed. By enhancing genetic selection processes, producers can improve herd health, reduce environmental impact, and optimize resource utilization.
With Neogen’s advanced genetic testing platform, Zoetis will be able to provide livestock producers with deeper insights into genetic potential and health risks at an earlier stage. Predictive analytics derived from genomic data can help identify animals that are more resilient to disease, better adapted to environmental conditions, or more efficient in converting feed into protein. These advantages translate into improved economic returns for producers while supporting sustainable livestock production practices.
Beyond livestock, genomics also holds significant promise in the companion animal sector. As pet owners increasingly seek personalized care and preventive health solutions, genetic insights can help veterinarians identify breed-specific risks and tailor health management strategies accordingly. By integrating genomic data into its broader product and service ecosystem, Zoetis aims to strengthen its ability to deliver individualized care solutions across species.
The transaction also reflects Zoetis’ disciplined approach to strategic investments. With a purchase price of $160 million, the acquisition represents a targeted expansion into a high-growth, innovation-driven segment. Zoetis expects to complete the transaction in the second half of calendar year 2026, subject to customary closing conditions and regulatory approvals. The company has expressed confidence in its ability to navigate the approval process and execute a smooth integration.
A key priority for Zoetis will be ensuring continuity for both customers and employees during the transition period. The company has committed to a seamless integration process designed to preserve Neogen’s legacy of innovation while aligning operations with Zoetis’ global standards and strategic objectives. By maintaining operational stability and customer service excellence, Zoetis aims to build on the strong relationships Neogen has established in the genomics market.
This acquisition also underscores the broader convergence of biotechnology and digital innovation in agriculture. The integration of genomic testing, advanced analytics, and software platforms enables a more holistic approach to animal health management. Producers can move beyond reactive treatment models toward proactive, preventive strategies rooted in predictive data. Such an approach not only enhances animal welfare but also contributes to food security and environmental stewardship.
In recent years, Zoetis has consistently invested in expanding its capabilities across diagnostics, digital solutions, and data analytics. The addition of Neogen’s genomics business represents another milestone in this journey, reinforcing the company’s position as a pioneer in applying scientific innovation to real-world agricultural challenges. By uniting genetic intelligence with therapeutic and preventive solutions, Zoetis is advancing a more integrated model of animal health.
As the livestock industry continues to evolve, the ability to harness genetic data effectively will be a key differentiator. The combination of Zoetis’ global reach and Neogen’s specialized genomics expertise is expected to accelerate innovation and expand access to advanced genetic tools worldwide. This partnership positions Zoetis to help shape the future of animal health by empowering producers with actionable insights that drive performance, resilience, and sustainability.
Ultimately, the acquisition reflects a shared vision of supporting healthier animals and more efficient food production systems. By leveraging the strengths of both organizations, Zoetis aims to deliver enhanced value to customers while contributing to a more sustainable and technologically advanced agricultural ecosystem. Through continued investment in genomics and Precision Animal Health, the company is reinforcing its commitment to innovation and its leadership role in the global animal health industry.
Source Link:https://www.businesswire.com/
